Costa Philippos A, Saul Eduardo E, Paul Yonette, Iyer Sunil, da Silva Laercio Lopes, Tamariz Leonardo, Lopes Gilberto
Division of Internal Medicine, Department of Medicine, Miller School of Medicine, University of Miami, Miami, FL.
Division of Hematology and Medical Oncology, Department of Medicine, Miller School of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.
JCO Oncol Pract. 2021 May;17(5):e629-e636. doi: 10.1200/OP.20.00961.
Inferior outcomes of Black patients with lung cancer compared with other racial groups are often linked to socioeconomic factors. It is crucial to determine whether a varying prevalence of targetable mutations limits treatments and contributes to disparities.
We conducted a meta-analysis on the prevalence of lung cancer , , , and mutations in Black patients compared with White, Hispanic, and Asian patients. We searched PubMed/MEDLINE, Cochrane Library, EMBASE, CENTRAL, Google Scholar, and clinicaltrials.gov databases. We selected studies reporting the prevalence of at least one mutation in the Black population. We calculated the pooled prevalence of mutations using fixed effects, exact binomial distributions, and Freeman-Turkey double arcsine transformation to stabilize the variances.
Twenty studies with 11,867 patients were included. In Black patients, was the most prevalent mutation (6%; 95% CI, 5 to 7), followed by (1%; 95% CI, 0 to 2), (1%; 95% CI, 0 to 2), and (0%; 95% CI, 0 to 1). Black patients had a lower prevalence of mutations than White, Hispanic, and Asian patients ( < .01). mutations were less prevalent in Black compared with White patients ( < .05), and mutations were less prevalent when compared with Hispanic patients ( < .05).
is the most frequent mutation found in Black patients, although its prevalence is lower than that in other races. Black patients have a low overall prevalence of , , and mutations. Given that disproportional eligibility for targeted therapies may be contributing to inferior outcomes, research focused on the Black population is needed to evaluate specific tumor characteristics and therapeutic strategies.
与其他种族群体相比，肺癌黑人患者的预后较差，这通常与社会经济因素有关。确定可靶向突变的不同患病率是否会限制治疗并导致差异至关重要。
我们对肺癌 、 、 和 突变在黑人患者与白人、西班牙裔和亚洲患者中的患病率进行了荟萃分析。我们检索了PubMed/MEDLINE、Cochrane图书馆、EMBASE、CENTRAL、谷歌学术和clinicaltrials.gov数据库。我们选择了报告黑人人群中至少一种突变患病率的研究。我们使用固定效应、精确二项分布和弗里曼-土耳其双反正弦变换来稳定方差，计算突变的合并患病率。
纳入了20项研究，共11867名患者。在黑人患者中， 是最常见的突变（6%；95%CI，5至7），其次是 （1%；95%CI，0至2）、 （1%；95%CI，0至2）和 （0%；95%CI，0至1）。黑人患者中 突变的患病率低于白人、西班牙裔和亚洲患者（ <.01）。与白人患者相比，黑人中 突变的患病率较低（ <.05），与西班牙裔患者相比， 突变的患病率较低（ <.05）。
是在黑人患者中发现的最常见突变，尽管其患病率低于其他种族。黑人患者中 、 和 突变的总体患病率较低。鉴于靶向治疗的不成比例的资格可能导致较差的结果，需要针对黑人人群进行研究，以评估特定的肿瘤特征和治疗策略。
